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Surgical Site Infection Research Opportunities
Kamal M.F. Itani,1 E. Patchen Dellinger,2 John Mazuski,3 Joseph Solomkin,4
George Allen,5 Joan C. Blanchard,6 Rachel Kelz,7 and Sandra I. Berrı´os-Torres8,*
Abstract
Much has been done to identify measures and modify risk factors to decrease the rate of surgical site infection
(SSI). Development of the Centers for Disease Control and Prevention (CDC) Core recommendations for the
prevention of SSI revealed evidence gaps in six areas: Parenteral antimicrobial prophylaxis, glycemic control,
normothermia, oxygenation, antiseptic prophylaxis, and non-parenteral antimicrobial prophylaxis. Using a
modified Delphi process, seven SSI content experts identified nutritional status, smoking, obesity, surgical
technique, and anemia as additional areas for SSI prevention research. Post-modified Delphi process Staphy-
lococcus aureus colonization and SSI definition and surveillance were also deemed important topic areas for
inclusion. For each topic, research questions were developed, and 10 were selected as the final SSI research
questions.
Keywords: anemia; antibiotic prophylaxis; glucose control; guideline; surgical site infection
The Centers for Disease Control and Prevention (CDC)and Healthcare Infection Control Practices Advisory
Committee (HICPAC) Guideline for the Prevention of Sur-
gical Site Infection (SSI) was developed using evidence-
based methodology with key questions provided by external
SSI content experts. This guideline is a targeted update to the
Guideline for the Prevention of Surgical Site Infection, 1999
[1]. The Core section recommendations were crafted using
randomized controlled trials (RCTs) and systematic reviews
of RCTs, across surgical specialties. The prosthetic joint
arthroplasty-specific section recommendations focused so-
lely on the evidence available for this single high-volume,
high-burden procedure. The evidence was rigorously evalu-
ated using the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) methodology [2].
Final recommendations for both sections are presented in the
2017 guideline [3].
The purpose of this article is to propose SSI research
questions based on both evidence gaps identified during the
Core section guideline development process and additional
questions proposed by the content experts. Content experts
agreed that new research should also include a cost-
effectiveness assessment of any preventative measure stud-
ied. The SSI research opportunities specific to prosthetic joint
arthroplasty procedures are addressed by the arthroplasty
content experts in a separate article [4].
Identifying SSI Research Areas
Potential SSI research areas and questions were derived
from two sources: (1) evidence gaps identified during the
Core section guideline development process and (2) addi-
tional research areas and questions proposed by content ex-
perts (Fig. 1).
SSI research areas based on guideline evidence gaps
In the updated CDC and HICPAC categorization scheme
for recommendations [5,6], key questions for which there
is either no evidence or low to very low-quality evidence
with uncertain trade-offs between benefits and harms are
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categorized as ‘‘No recommendation/unresolved issue’’ and
can be deemed to represent ‘‘evidence gaps.’’ All six Core
section key topics (parenteral antimicrobial prophylaxis
[AMP], non-parenteral AMP, glycemic control, normother-
mia, oxygenation, and antiseptic prophylaxis) had some evi-
dence gaps (Fig. 1).
Additional SSI research areas proposed
by the content experts
The content experts initially identified 31 areas for SSI
research (Fig. 1) and prioritized them using a modified
Delphi process [7]. Twenty-two areas received at least one
vote. Of the 10 areas that received at least four votes, con-
sensus was reached to eliminate eight (five already addressed
as guideline evidence gaps and three suggested by the
content experts), leaving obesity (6 votes) and surgical
technique (5 votes) as research areas. There was also con-
sensus to include smoking and anemia (3 votes each) and
malnutrition (1 vote). Post-modified Delphi process, Sta-
phylococcus aureus colonization (a topic originally sug-
gested for inclusion in the guideline) and SSI definition and
surveillance (which impact SSI rates and reporting) were
included in the final 13 research areas (Fig. 1).
Identifying research questions
Fifty-two questions were crafted in 13 research areas
(Tables 1 and 2). Those questions receiving three or more
votes were selected as final SSI research questions (Table 1).
Eight questions represent guideline Core section evidence
gaps, and two were identified from research areas identified
by the content experts. The 42 remaining questions represent
additional SSI research opportunities (Table 2).
Final SSI Research Areas
Parenteral AMP: Timing, dosing, re-dosing, duration
There are many outstanding questions surrounding the
timing of antimicrobial agents before surgery and how im-
proving this timing for particular classes or agents used for
specific surgeries might reduce SSI further. A recent large
retrospective study confirmed that the current practice of
administering parenteral AMP within 60 minutes of incision
Content Expert Identified Research Areas −Modified Delphi Process
Guideline Core Section Areas with Evidence Gaps
Peri-operative antimicrobial prophylaxis [AMP] a
Non-parenteral AMP a
Glycemic control a
Normothermia a
Oxygenation a
Antiseptic prophylaxisa
Obesityb
Surgical techniqueb
Smokingb
Anemiab
Malnutritionb
Staphylococcus aureus colonizationc
SSI definition and surveillancec
a Guideline evidence gap[s]
b Identified by content experts–modified Delphi process 
c Included by content experts post-modified Delphi approach
Parenteral antimicrobial prophylaxis [AMP]
Non-parenteral AMP 
Glycemic control
Normothermia
Oxygenation
Antiseptic prophylaxis
6 votes
Obesity
Antimicrobial dressingsa
Drains
5 votes
Antimicrobial irrigationa
Antimicrobial coated suturesa
Antiseptic showersb
Surgical technique 
Gloves
4 votes
Non-parenteral AMPa
Surgical attire
3 votes
Smoking
Anemia 
Steroids
Non-steroidal immunosuppressant therapy
Remote site infection
Pre-operative hospitalization
2 votes
Discharge planning
Hair removal
1 vote
Malnutrition 
Asepsisb
Presence of open wound
Environmental surfaces
No votes
Pre-operative stay [long-term or nursing home 
facilities]
Type of procedures
Skin disorders
Peripheral vascular disease
Transplantation
Post-operative wound healing
Laminar flow/high-efficiency particulate 
absorption [HEPA]
Other environmental issues
Cleaning
a Addressed in guideline: Non-parenteral AMP
b Addressed in guideline: Antiseptic Prophylaxis
Final SSI Research Areas
FIG. 1. Surgical site infection research areas.
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for all antimicrobial agents and across specialties might not
be optimal [8]. The need for and optimal timing of intra-
operative parenteral AMP re-dosing and whether subsequent
doses should be the same as the initial pre-operative dose in
obese versus non-obese patients have not been studied [9].
Whether discontinuation of parenteral AMP beyond skin
closure in the operating room is appropriate in clean con-
taminated cases is also poorly studied [10,11].
Non-parenteral AMP: Antimicrobial irrigation,
ointments, powders, dressings
According to the guidelines, no antimicrobial agent such as
ointments, solutions, powders, or sealants should be applied
to the wound. Irrigation of the deep and subcutaneous tissues
with aqueous iodophor solution can be considered. No rec-
ommendation could be made regarding antimicrobial dress-
ings applied immediately after primary wound closure in the
operating room. Opportunities for prevention of SSI by local
prevention as opposed to systemic administration continue to
exist as new agents and delivery system evolve.
Glycemic control: Peri-operative glycemic control;
hemoglobin A1C levels and risk of SSI
While avoidance of severe hyperglycemia is recognized as
key to the care of all hospitalized patients and important in
the prevention of SSI, the degree to which hyperglycemia
should be controlled to prevent SSI remains unclear [12,13].
The frequency and post-operative duration of peri-operative
glucose monitoring has not been evaluated rigorously. The
degree to which hyperglycemia should be controlled has been
subject to a number of investigations but has proven ex-
tremely controversial [14,15]. Studies with less rigorous de-
signs have shown that maintenance of improved glycemic
control (although not necessarily strict glycemic control) was
associated with improved outcomes, including reduced rates
of SSI in patients undergoing cardiac surgery [16–19]. High
glucose variability has been associated with higher risk of
acquired infection and death in patients in medical-surgical
intensive care units; therefore, glycemic control focused on
maintaining an absolute blood glucose target level at a single
point in time might warrant re-evaluation [20].
Data regarding hemoglobin A1C levels as a marker of pre-
operative glucose control and its association with SSI are also
lacking. One hypothesis is that while elevated A1C levels are
associated with a higher risk of hyperglycemia in the peri-
operative period, the hyperglycemia itself is the important
SSI risk factor, not the A1C level [21].
Normothermia: Mechanism, lower limit, normothermia
ratio, strategies to achieve and maintain
It has been hypothesized that normothermia prevents SSI
by reducing vasoconstriction, thereby improving oxygen
delivery at the incision [22,23]. Whether normothermia, in-
dependent of oxygenation, optimizes metabolic and enzy-
matic activities essential in incision healing mechanisms and
the killing of micro-organisms, thus reducing the risk of SSI,
remains unknown, however. Also, whether systemic nor-
mothermia accurately reflects temperature at the incision
warrants further study. In addition, hypothermia is associated
with greater degrees of intra-operative blood loss that in
many analyses is an additional risk factor for SSI [22,23].
The lower limit of temperature in normothermia and its
duration post-operatively have been inconsistently defined.
Research to identify a break point ‘‘normothermia ratio’’ for
Table 1. Final Surgical Site Infection Research Questions
Parenteral antimicrobial prophylaxis (AMP)*
 What is the optimal timing of pre-operative parenteral AMP that reduces the risk of surgical site infection (SSI)?*
 What are the criteria for intra-operative re-dosing of parenteral AMP that reduce the risk of SSI?*
Non-parenteral AMP*
 How safe and effective is intra-operative antimicrobial irrigation in reducing the risk of SSI?*
Glycemic control*
 How do pre-operative hemoglobin A1C levels impact the risk of SSI and what are their optimal pre-operative target
levels in diabetic and non-diabetic patients?*
Normothermia*
 What are the most effective strategies for achieving and maintaining peri-operative normothermia?*
Oxygenation*
 What is the optimal target fraction of inspired oxygen [FiO2] to reduce the risk of SSI; how and when should it be
administered?*
 What is the relevant role of each: Optimal oxygenation, normothermia, normovolemia, and type of anesthesia
(neuraxial versus general) in the risk of SSI?
Antiseptic prophylaxis*
 For pre-operative bathing or showering, what is the optimal agent, timing, number of product applications at each
session, and frequency of showers/baths that reduce the risk of SSI?*
Smoking
 What is the optimal timing of pre-operative smoking cessation that results in substantial reduction in the risk of SSI?
Surgical technique
 What is the optimal subcutaneous tissue closure (e.g., suture type, spacing, etc.) that reduces the risk of SSI in various
patients (e.g., surgical procedures, obese patients, etc.)?
*From the Centers for Disease Control and Prevention and Healthcare Infection Control Practices Advisory Committee’s Guideline for
the Prevention of Surgical Site Infection, 2017.
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Table 2. Additional Surgical Site Infection Research Opportunities
Parenteral antimicrobial prophylaxis (AMP)*
 What is the optimal AMP dosing for various agents?
Non-parenteral AMP*
 How safe and effective are non-parenteral antimicrobial agents applied to the surgical incision?*
 How safe and effective are antimicrobial dressings applied to the surgical incision following primary closure in the
operating room?*
Glycemic control*
 Should hemoglobin A1C levels be checked routinely on all patients undergoing elective surgical procedures?
 Is there a particular hemoglobin A1C level that would justify screening and intervention to prevent surgical site infection (SSI)?
 Is there a safe blood glucose value or range that should be targeted in the peri-operative period to prevent SSI in surgical
patients?
Normothermia*
 What is the lower temperature limit of normothermia?*
 What is the optimal timing and duration of normothermia?*
 Identify a break point ‘‘normothermia ratio’’ for higher SSI.
 Does systemic normothermia reflect the same temperature as the wound?
Oxygenation*
 How does increased FiO2 impact the risk of SSI in patients undergoing neuraxial anesthesia?*
 Is FiO2 a good surrogate of oxygen saturation at the wound? What is the best method and body location for measuring oxygen saturation?
Antiseptic prophylaxis*
 Are there specific patient groups that would benefit to a greater extent from pre-operative showers or bathing?
 Is antiseptic irrigation useful for all wound classes? Which antiseptic agent?
 Is there a role for application of antiseptic agents directly to the surgical incision?
Nutritional status
 What is the best way of characterizing pre-operative nutritional status’ impact on SSI?
 How does pre-operative serum albumin level impact the risk of SSI?
 Does pre-operative specialized nutritional support decrease the risk of SSI?
 Are there patients or types of surgery where pre-operative specialized nutritional support would decrease the risk of SSI?
Smoking
 What is the differential contribution to SSI of smoking duration and/or amount?
Obesity
 What is the relative contribution to SSI of obesity alone versus obesity and other associated obesity co-morbid conditions
and factors?
 How do we best quantify obesity in the prevention of SSI? Weight, body mass index, or other morphometric measurements?
 How does pharmacokinetics in obese patients affect the use of parenteral and non-parenteral antimicrobial and
antiseptic agents?
 Does subcutaneous tissue perfusion in obese patients contribute differently to SSI than non-obese patients?
Surgical technique
 What is the correlation between the amount of electrocautery use on the skin and subcutaneous tissue and risk of SSI?
 What is the correlation between the amount of tissue pressure and tension applied intra-operatively and risk of SSI?
 When should a drain be placed in the subcutaneous space and when should it be removed to reduce the risk of SSI?
Anemia
 Is anemia a risk factor for SSI?
 Is blood transfusion a risk factor for SSI or is it a surrogate for other SSI risk factors such as operations that are more difficult,
take longer, require more dissection, and therefore result in more blood loss?
 Is there a cutoff point for blood transfusion below which peri-operative transfusions should be done but above which they
should be withheld in order to decrease the risk of SSI?
 Is the risk of SSI higher with ‘‘older’’ blood transfusions?
 How does parenteral iron, oral iron, or recombinant human erythropoietin used to correct pre-operative anemia impact the risk
of SSI?
Staphylococcus aureus (SA) colonization
 Is SA colonization an independent risk factor for SA SSI?
 Does SA decolonization reduce risk of SSI?
 Does parenteral AMP with vancomycin in patients colonized with methicillin-resistant S. aureus (MRSA) reduce the risk of
MRSA SSI?
 Should all surgical patients undergo screening for SA (MRSA/methicillin-sensitive S. aureus)?
SSI surveillance
 Does diagnosis of SSI by the attending physician or surgeon introduce bias in reporting?
 Could responsibility for SSI surveillance shift to personnel who are not familiar with surgical wounds?
 Could SSI surveillance shift to monitoring by natural language processing of electronic medical records and how would it
compare to surveillance using administrative databases?
 Will the implementation of ICD-10 coding allow for SSI surveillance using administrative databases?
 Should subjective criteria such as Celsian signs and quality of wound discharge be substituted by an objective scoring system
for the diagnosis of SSI?
*From the Centers for Disease Control and Prevention and Healthcare Infection Control Practices Advisory Committee’s Guideline for
the Prevention of Surgical Site Infection, 2017.
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higher SSI rates would be important. The denominator for
that ratio is the duration of time (min) from arrival to the
operating room up to a defined time post-operatively to be
determined (2–5 h). The numerator for that ratio would
consist of the amount of time (min) a patient’s core temper-
ature is above a pre-defined minimum temperature level for
that period in the denominator. Finally, the most effective
strategy to achieve and maintain peri-operative normother-
mia remains unknown.
Oxygenation: Optimal delivery, measurement
While multiple human and animal studies have demon-
strated the relationship between higher oxygen levels and the
increased ability of white blood cells to kill bacteria at the
surgical wound [24–26], the best method and body location
to measure oxygen saturation/tissue oxygenation has not
been determined. The guideline recommendation states
that: ‘‘For patients with normal pulmonary function under-
going general anesthesia with endotracheal intubation, ad-
minister increased fraction of inspired oxygen (FiO2) both
intra-operatively and post-extubation in the immediate post-
operative period. To optimize tissue oxygen delivery, main-
tain peri-operative normothermia and adequate volume
replacement.’’ (Category IA-strong recommendation) [3].
Optimal delivery of oxygen to the wound site and the degree
to which it is influenced by inspired oxygen fraction remains
unknown, however.
Antiseptic prophylaxis: Pre-operative bathing/
showering, intra-operative skin preparation
While commonly performed, the effectiveness of pre-
operative bathing or showering with an antiseptic or non-
antiseptic agent in reducing the risk of SSI has not been
determined firmly. Variable results in this fieldmay be because
of differences in the agent used, timing, frequency, andmethod
by which the agents are applied within and across trials. For
intra-operative surgical site antiseptic skin preparation, the
relative efficacy of iodophors compared with chlorhexidine
gluconate and the relative contribution of alcohol to the effi-
cacy of these agents warrant further investigation.
Malnutrition: Optimizing pre-operative nutrition
Malnourishment is a known risk factor for infection [27].
Some nutritional interventions could decrease the risk of SSI
in malnourished patients undergoing elective surgical pro-
cedures [28,29]. Based in part on the results of a large United
States Department of Veterans Affairs study published in
1991 [30], pre-operative parenteral nutrition is not re-
commended for most patients undergoing elective surgical
procedures, unless they are moderately to severely mal-
nourished. Studies of pre-operative enteral nutrition have
given conflicting results. Based on a number of small studies,
pre-operative enteral nutrition, particularly immunonutrition,
has been endorsed in some guidelines and reviews [31–33].
Immunonutrition refers to immune-modulating nutrition
products (hydrolyzed peptide-based protein formulas with
some combination of fish oils such as eicosapentaenoic acid,
and docosahexaenoic acid), arginine, nucleic acids, anti-
oxidants believed to work by increasing cell membrane sta-
bility, improving gastrointestinal mucosal integrity, enhancing
cell-mediated immune responses, attenuating inflammatory
responses to stress, and improving blood flow to poorly vas-
cularized and ischemic tissue [34]. Many of the studies sup-
porting pre-operative nutritional therapy have had significant
methodologic flaws, the data have been heterogeneous, and all
infectious complications, not SSI per se, have been the primary
end point for many of them. A recent study of patients un-
dergoing total gastrectomy for gastric cancer found that pre-
operative immunonutrition did not impact the risk of SSI [35].
Smoking: Optimizing pre-operative cessation
While there is strong evidence that smoking is a major risk
factor for SSI and that smoking cessation intervention re-
duces that risk [36], whether a smoking threshold for in-
creased risk of SSI exists is not known. The optimal timing of
pre-operative smoking cessation that results in substantial
reduction in SSI is unknown.
Obesity: Contribution to SSI risk, optimizing
measurement
Obesity, a known risk factor for SSI [37,38], is associated
with multiple co-morbidities (e.g., diabetes mellitus, meta-
bolic syndrome, increased American Society of Anesthe-
siologists class, tissue hypoperfusion, and prolonged surgical
procedures); however, the relative contributions to SSI risk of
obesity alone and obesity in combination with these factors is
unknown. Obesity has been characterized by descriptors such
as weight, body mass index, subcutaneous fat at the site of
incision, excess body fat, percent body fat, and other mor-
phometric body measurements, but the best measure as
predictor of SSI risk remains elusive. While tissue pene-
tration of parenteral antimicrobial agents at the site of in-
cision has been shown to be dependent on dosing in obese
patients, the differences in the pharmacokinetics of vari-
ous antimicrobial agents between normal weight and obese
patients have been studied poorly. The impact of the type of
subcutaneous tissue closure, (including whether or not to
use a drain), on the risk of SSI in obese patients, remains
unknown. The amount of fat relative to capillary perfusion
in animal models and the optimization of perfusion might
elucidate issues related to hypoperfusion, improved oxygen
tension, and antimicrobial tissue penetration.
Surgical techniques: Electrocautery, tissue handling,
subcutaneous and skin closure
Surgical technique might impact operative time, blood
loss, and intra-operative contamination, all of which in turn
impact SSI risk. Although these factors have been used as
surrogates, they are not a direct measure of surgical tech-
nique. Quantifying the use of electrocautery and the extent to
which it devitalizes tissue and contributes to SSI should be
studied. Similarly, tissue handling by measuring the amount
of tension and pressure applied to tissue and its contribution
to SSI should be investigated. The optimal type of subcuta-
neous and skin closure in obese and non-obese patients un-
dergoing a variety of surgical procedures, skin closure versus
no closure, size and spacing of fascial sutures, placement and
timing of removal of drains should be explored further.
SSI RESEARCH OPPORTUNITIES 405
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Anemia: Peri-operative anemia, blood transfusion
The lower hemoglobin value to define anemia resulting in
SSI is unknown. The association between pre-operative
anemia and SSI risk differs between publications [39,40].
Anemia might reduce oxygen transport to the surgical in-
cision, impairing antibacterial mechanisms and incision
healing, increasing the risk of SSI. It might, however, simply
be associated with other medical conditions that increase
infection risk. Some studies have demonstrated an associa-
tion between peri-operative blood transfusion and an in-
creased risk of SSI [41–43]. In addition, patients with anemia
are likely to be at increased risk of receiving a peri-operative
blood transfusion [44]. The relative risks of anemia and
transfusion are unknown.
S. aureus colonization
Staphylococcus aureus is the micro-organism most com-
monly associated with SSI. In addition, the overall incidence
of SSI because of both methicillin-sensitive S. aureus and
methicillin-resistant S. aureus (MRSA) strains is increasing
[45]. Colonization with S. aureus, present in 25%–30% of
persons in the community, is a recognized risk factor for SSI
[46]. Thus, approaches to the identification and decolonization
of S. aureus carriers could reduce the risk of S. aureus SSI.
High-quality evidence on the decolonization of staphylococci
from the nasopharynx and its effectiveness in reducing the risk
of S. aureus SSI is limited. In a large meta-analysis of ortho-
pedic and cardiac surgical patients, decolonization was asso-
ciated with a lower incidence of gram-positive SSI [47];
however, decolonization appeared to be less effective in pa-
tients undergoing other surgical procedures [48].
In a large randomized double-blind placebo-controlled
study, prophylactic intranasal application of mupirocin did
not significantly reduce the rate of S. aureus SSI [49]. In a
recent trial, combined pre-operative bathing with chlorhex-
idine gluconate and nasal decolonization resulted in a signifi-
cant reduction in S. aureus SSI in a population inwhichMRSA
was nearly absent [50]. Overall rates of SSI were not reported,
however. There are significant logistic and cost-related issues
associated with programs for screening and decolonization of
S. aureus carriers and increasing concerns about emerging
bacterial resistance to mupirocin [51]. Additional research to
identify those patients who would most likely benefit from
targeted screening and decolonization as well as the optimal
means of performing both is warranted.
SSI definition and surveillance
Differences in SSI rates reported for similar surgical pro-
cedures may reflect different interpretations of SSI defini-
tions, inconsistent coding, or variability in the intensity
of surveillance (particularly post-discharge surveillance).
Although the CDC SSI surveillance definitions are the most
widely used [52,53], many have called for improvement in
both the definition and surveillance of SSIs.
Surgeons have questioned the categorization of SSI into
superficial, deep incisional, and organ/space [54,55]. Super-
ficial SSIs are the most common. While they are less likely to
be associated with increased length of hospital stay and cost
[54], they continue to be an outcome of major significance to
the patient and surgeon. It has also been postulated that su-
perficial infections are the SSIs most likely to be identified
after discharge from either outpatient or inpatient operations
and thus potentially go undetected by surveillance mecha-
nisms [55]. In contrast, deep incisional and organ/space SSIs
are most commonly detected on admission and re-admission
to the hospital and therefore are not subject to the variability
in identification or post-discharge surveillance. For public
reporting purposes, deep incisional and organ/space SSIs are
combined into a single category. In select procedures, organ/
space infections can result from a technical failure such as an
anastomotic leak in bowel operations. Whether technical
failure-related organ/space infections should continue to be
combined with other organ/space infections for public re-
porting purposes remains a topic of discussion. More re-
search will need to be performed to validate or refute these
concepts. In addition, there needs to be uniform policies and
support for those surveillance strategies that are deemed to
be most effective.
Conclusion
Over the years, important strides advancing our knowledge
in the prevention of SSI have been made. Recommendations
made in the accompanying CDC and HICPAC Guideline
for the Prevention of Surgical Site Infection are based on
RCT-level evidence and reveal substantial gaps that deserve
our consideration for future research that will also address the
cost-effectiveness of those measures. This article presents
opportunities for SSI research focusing on prevention effec-
tiveness and high-yield questions to help prioritize SSI re-
search opportunities over the next few years.
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